Anglo-Australian collaboration to advance T-cell production technology

The UK’s Cell and Gene Therapy Catapult (CGT) and its Australian counterpart have signed an agreement to advance scaffold technology for commercial production of T-cells.

Together, the government-backed initiatives, which were set up to help turn academic and industry-led research into life-changing medicines, will test at scale the patented scaffold technology of the Australian Center for Translation of Cell Therapy Technologies (CTM CRC).

This technology is designed for T-cell stimulation and expansion, and the testing by CGT will provide independent supporting data for ultimate commercial scale-up. The consortium will then investigate opportunities to apply this technology to commercial scale cell expansion systems.